scholarly journals Usefulness of J-CAPRA Score for High-risk Prostate Cancer Patients Treated with Carbon Ion Radiotherapy Plus Androgen Deprivation Therapy

2014 ◽  
Vol 44 (4) ◽  
pp. 360-365 ◽  
Author(s):  
K. Akakura ◽  
H. Tsuji ◽  
H. Suzuki ◽  
T. Ichikawa ◽  
H. Ishikawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

scholarly journals Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer

2009 ◽  
Vol 2009 ◽  
pp. 1-8 ◽  
Author(s):  
Piotr Milecki ◽  
Maciej Baczyk ◽  
Janusz Skowronek ◽  
Andrzej Antczak ◽  
Zbigniew Kwias ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Progression Free Survival ◽  
Androgen Deprivation ◽  
Pelvic Radiotherapy ◽  
Prostate Radiotherapy ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Aim. To study whether use of neoadjuvant androgen deprivation therapy (N-ADT) combined with whole pelvic radiotherapy (WPRT) for high-risk prostate cancer patients was associated with survival benefit over prostate radiotherapy (PORT) only.Material and Methods. Between 1999 and 2004, 162 high-risk prostate cancer patients were treated with radiotherapy combined with long-term androgen deprivation therapy (L-ADT). Patients were prospectively assigned into two groups: A (N-ADT + WPRT + L-ADT) = 70 pts, B (PORT + L-ADT) = 92 pts.Results. The 5-year actuarial overall survival (OS) rates were 89% for A and 78% for B ( = .13). The 5-year actuarial cause specific survival (CSS) rates were A = 90% and B = 79% ( = .01). Biochemical progression-free survival (bPFS) rates were 52% versus 40% ( = .07), for groups A and B, respectively.Conclusions. The WPRT combined with N-ADT compared to PORT for high-risk patients resulted in improvement in CSS and bPFS; however no OS benefit was observed.

scholarly journals Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy

2017 ◽  
Vol 23 (22) ◽  
pp. 6802-6811 ◽  
Author(s):  
Himisha Beltran ◽  
Alexander W. Wyatt ◽  
Edmund C. Chedgy ◽  
Adam Donoghue ◽  
Matti Annala ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document